Eupraxia Pharmaceuticals (EPRX) Investor presentation summary

Study design and objectives

• Phase 1b/2a multicenter, open-label, dose-escalation trial evaluates safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with eosinophilic esophagitis.

• EP-104GI is a long-acting, submucosal injectable fluticasone propionate designed for controlled, localized drug release.

• Doses are escalated from 4×1mg up to 16×4mg, with follow-up up to 52 weeks.

• Efficacy assessed by peak eosinophil counts, EoE histology scoring, and Straumann Dysphagia Index.

Safety and tolerability

• No dose-limiting toxicity or serious adverse events observed to date.

• Serum glucose and cortisol levels remained stable post-administration.

• Most treatment-emergent adverse events were unlikely related to EP-104GI; related events included mild chest pain, nausea, throat tightness, and esophageal sensitivity.

• No gastrointestinal candidiasis or adrenal suppression reported.

Pharmacokinetics

• Systemic fluticasone levels remained low and constant (<20 pg/mL) after an initial peak, across all dose levels.